A0200000
Ácido acetilsalicílico
European Pharmacopoeia (EP) Reference Standard
Sinônimo(s):
Ácido O-acetilsalicílico, AAS, Aspirina, Ácido 2-acetoxibenzoico
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Fórmula linear:
2-(CH3CO2)C6H4CO2H
Número CAS:
Peso molecular:
180.16
Beilstein:
779271
Número MDL:
Código UNSPSC:
41116107
ID de substância PubChem:
NACRES:
NA.24
Produtos recomendados
grau
pharmaceutical primary standard
família API
aspirin
fabricante/nome comercial
EDQM
pf
134-136 °C (lit.)
aplicação(ões)
pharmaceutical (small molecule)
formato
neat
temperatura de armazenamento
2-8°C
cadeia de caracteres SMILES
CC(=O)Oc1ccccc1C(O)=O
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
chave InChI
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Informações sobre genes
human ... PTGS1(5742) , PTGS2(5743)
Procurando produtos similares? Visita Guia de comparação de produtos
Categorias relacionadas
Descrição geral
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicação
Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Ações bioquímicas/fisiológicas
Bloqueia a produção de prostaglandinas pela inibição da ciclo-oxigenase (prostaglandina H sintase), com maior seletividade para a isoforma COX-1. O efeito antitrombótico se deve à inibição de COX-1 nas plaquetas que bloqueiam a produção de tromboxano e a agregação de plaquetas. Atividade quimiopreventiva contra tumores colorretais e outros tumores sólidos.
Embalagem
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Outras notas
Sales restrictions may apply.
produto relacionado
Nº do produto
Descrição
Preços
Palavra indicadora
Warning
Frases de perigo
Declarações de precaução
Classificações de perigo
Acute Tox. 4 Oral
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 1
Ponto de fulgor (°F)
482.0 °F
Ponto de fulgor (°C)
250 °C
Choose from one of the most recent versions:
Certificados de análise (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Atendimento ao cliente
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Os clientes também visualizaram
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
T N Bonten et al.
Thrombosis and haemostasis, 112(6), 1209-1218 (2014-09-12)
The risk of acute cardiovascular events is highest during morning hours, and platelet activity peaks during morning hours. The effect of timing of aspirin intake on circadian rhythm and morning peak of platelet reactivity is not known. It was our
J W Eikelboom et al.
Journal of thrombosis and haemostasis : JTH, 3(12), 2649-2655 (2005-12-20)
We aimed to determine whether adding clopidogrel to aspirin in patients at high risk of future cardiovascular events would suppress laboratory measures of the antiplatelet effects of aspirin; and have greater platelet inhibitory effects in patients with the least inhibition
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica